Effects of NSAIDS on cryoprobe-induced gastric ulcer healing in rats

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 12, 2001, Pages 2001-2008

  Tibble, J ^a   Sigthorsson, G ^a   Caldwell, C ^a   Palmer, R H ^b   Bjarnason, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; INDOMETACIN; KI 67 ANTIGEN; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; STOMACH ULCER; ULCER HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; CELL DIVISION; CYCLOOXYGENASE INHIBITORS; EPITHELIAL CELLS; GASTRIC MUCOSA; INDOMETHACIN; MALE; PROSTAGLANDINS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; STOMACH ULCER; SULFONAMIDES; WOUND HEALING;

EID: 0035659345     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01126.x     Document Type: Article

References (53)

1. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis
2. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: Risk factors and frequency of complications
3. Gastro intestinal safety of nonsteroidal antiinflammatory drugs
4. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicenter double blind, placebo-controlled trial
5. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
6. Healing of peptic ulcers during continuing anti-inflammatory drug therapy in rheumatoid arthritis
7. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drugs
8. Risk of bleeding peptic ulcers associated with individual non-steroidal anti-inflammatory drugs
9. Towards a GI safer antiinflammatory therapy
10. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
11. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
12. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity
13. Gastrointestinal safety profile of meloxicam: A meta-analysis and systematic review of randomized controlled trials
14. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury
15. The relative importance of inhibition of cyclooxygenase and uncoupling of oxidative phosphorylation in the gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
16. Early pathogenic events in NSAID-induced gastrointestinal damage
17. Expression of nitrogen-responsive gene encoding synthase is regulated by mRNA splicing
18. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
19. Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
20. Pharmacological analysis of cyclooxygenase-1 in inflammation
21. Dual inhibition of both cyclooxygenase (COX)-1 and COX-2 is required for NSAID-induced erosion formation
22. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induced epithelial prostaglandin synthase-2 expression and prostaglandin E2 and F2alpha production
23. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
24. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomised controlled trial
25. Gastrointestinal toxicty with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomised controlled trial. Celecoxib Long-Term Arthritis Study
26. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events
27. Safety and efficacy of nabumetone in osteoarthritis: Emphasis on gastrointestinal safety
28. 4-Nitro-2-phenoxymethanesulfonanilide (R-805): A chemically novel anti-inflammatory agent
29. Rofecoxib [Vioxx MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
30. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat
31. Influence of prostaglandins, omeprazole, and indomethacin on healing of experimental gastric ulcers in the rat
32. Inhibitory effect of non steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing
33. Inhibition of prostanoid synthesis by human gastric mucosa
34. Activity of nimesulide on constitutive and inducible cyclooxygenases
35. Monoclonal antibocdy KI-67: Its use in histopathology
36. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis
37. Intra cellular calcium homeostasis
38. Mechanism of ulcer healing and effects of nonsteroidal anti-inflammatory drugs
39. Antacids provide better restoration of glandular structure within the ulcer scar than omeprazole
40. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation
41. Metabolism of nabumetone (BRL 14777) by various species including man
42. COX-1, COX-2, COX-3 and the future treatment of chronic inflammatory disease
43. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
44. COX-2 inhibitors. A new class of antiangiogenic agents
45. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
46. Aspirin for cancer
47. A nuclear receptor to prevent colon cancer
48. Molecular pathology of cyclooxygenase-2 in neoplasia
49. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models
50. Controversies in NSAID-induced gastroduodenal damage - Do they matter?
51. NSAID activate quiescent inflammatory bowel disease
52. Analgesic ingestion and other factors preceding relapse in ulcerative colitis